文献速递乳腺癌

乳腺癌具有免疫原性:免疫学分析及使用突变反应性自体淋巴细胞的II期试点临床试验

Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.
PubMed 文献 · J Clin Oncol · 2022-02-01

该研究分析42例转移性乳腺癌患者的肿瘤突变免疫原性,并从切除病灶分离肿瘤浸润淋巴细胞(TIL)。28例(67%)患者TIL可识别至少一个免疫原性体细胞突变,8例符合治疗条件,6例入组接受富集新抗原特异性TIL联合帕博利珠单抗治疗,3例出现客观肿瘤消退。

要点

  • 42例转移性乳腺癌患者中,28例(67%)检出可识别至少一个免疫原性体细胞突变的TIL。
  • 6例患者接受新抗原特异性TIL联合帕博利珠单抗(≤4剂)治疗,3例出现客观肿瘤消退。
  • 1例完全缓解持续超过5.5年,2例部分缓解分别持续6个月和10个月。

核心结论

  • 多数乳腺癌患者可产生针对自身肿瘤突变表达产物的天然免疫反应。
  • TIL过继转移是转移性乳腺癌患者高度个体化的实验性选择,在本试点试验中可介导客观缓解,值得进一步研究。

研究设计与样本

  • 研究纳入42例既往多线治疗难治的转移性乳腺癌患者,行转移病灶手术切除、TIL培养分离、外显子组非同义肿瘤突变鉴定及新抗原反应性免疫筛选。
  • 临床合格且具有适当反应性的患者入组一项正在进行的II期试点试验的一个队列,接受选择性新抗原反应性TIL过继细胞转移联合短程帕博利珠单抗治疗(ClinicalTrials.gov标识符:NCT01174121)。

主要发现

  • 全部42例转移性乳腺癌患者的切除病灶均成功分离并培养出TIL,每例患者鉴定出的非同义突变中位数为112个(范围:6-563)。
  • 42例中28例(67%)含有可识别至少一个免疫原性体细胞突变的TIL,每例患者识别的新抗原中位数为3个(范围:1-11)。
  • 13例患者表现出适合过继转移的强反应性,8例仍符合临床治疗条件,6例入组接受富集新抗原特异性TIL过继细胞转移联合帕博利珠单抗(≤4剂)治疗。
  • 3例患者观察到客观肿瘤消退,包括1例完全缓解(现已持续超过5.5年)和2例部分缓解(分别持续6个月和10个月)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Metastatic breast cancer (mBrCa) is most often an incurable disease with only modest responses to available immunotherapies. This study investigates the immunogenicity of somatic mutations in breast cancer and explores the therapeutic efficacy in a pilot trial of mutation-reactive tumor-infiltrating lymphocytes (TILs) in patients with metastatic disease. PATIENTS AND METHODS: Forty-two patients with mBrCa refractory to previous lines of treatment underwent surgical resection of a metastatic lesion(s), isolation of TIL cultures, identification of exomic nonsynonymous tumor mutations, and immunologic screening for neoantigen reactivity. Clinically eligible patients with appropriate reactivity were enrolled into one cohort of an ongoing phase II pilot trial of adoptive cell transfer of selected neoantigen-reactive TIL, with a short course of pembrolizumab (ClinicalTrials.gov identifier: NCT01174121). RESULTS: TILs were isolated and grown in culture from the resected lesions of all 42 patients with mBrCa, and a median number of 112 (range: 6-563) nonsynonymous mutations per patient were identified. Twenty-eight of 42 (67%) patients contained TIL that recognized at least one immunogenic somatic mutation (median: 3 neoantigens per patient, range: 1-11), and 13 patients demonstrated robust reactivity appropriate for adoptive transfer. Eight patients remained clinically eligible for treatment, and six patients were enrolled on a protocol of adoptive cell transfer of enriched neoantigen-specific TIL, in combination with pembrolizumab (≤ 4 doses). Objective tumor regression was noted in three patients, including one complete response (now ongoing over 5.5 years) and two partial responses (6 and 10 months). CONCLUSION: Most patients with breast cancer generated a natural immune response targeting the expressed products of their cancer mutations. Adoptive transfer of TIL is a highly personalized experimental option for patients with mBrCa shown to be capable of mediating objective responses in this pilot trial and deserves further study.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Zacharakis N, Huq LM, Seitter SJ, et al. Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes. J Clin Oncol. 2022. PMID: 35104158. doi:10.1200/JCO.21.02170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。